Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. is a life sciences company that provides products enabling the development of drug therapies, vaccines, cell and gene therapies, and diagnostics. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, including reagents for chemical synthesis, modification, labeling, and purification of DNA and RNA. It also offers messenger RNA, oligonucleotides, CleanCap capping technology-based building blocks, custom enzyme development, and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for biologic manufacturing process development, including custom antibody and assay development services, HCP ELISA kits, bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.

Maravai LifeSciences Holdings, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MRVI. Its securities are traded in United States Dollars (USD). The company is headquartered in the United States and operates within the US region, with its stock available for trading on this major US exchange.

Maravai LifeSciences Holdings, Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. This means the company is involved in using biological processes and organisms to develop products and technologies that improve healthcare, such as therapies, vaccines, and diagnostics. As a biotechnology firm, it focuses on research and development of innovative solutions for medical and scientific applications.

Maravai LifeSciences Holdings, Inc. serves customers across multiple regions worldwide, including North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. This global reach allows the company to supply its life sciences products—such as nucleic acids for diagnostic and therapeutic applications, and antibody-based detection products—to biopharmaceutical companies and research institutions around the world. The company's products address key phases of biopharmaceutical development, supporting clients in various geographies.

Maravai LifeSciences generates revenue through its two business segments: TRILINK and CYGNUS. The TRILINK segment earns revenue by manufacturing and selling products used in gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This includes reagents for DNA and RNA synthesis, messenger RNA, oligonucleotides, CleanCap capping technology, and custom enzyme development. The CYGNUS segment generates revenue by selling analytical products for biologic manufacturing process development, such as custom antibody and assay development services, HCP ELISA kits, bioprocess impurity kits, and viral clearance prediction kits. The company serves biopharmaceutical companies, providing critical tools for drug development and production.